Star Fox launches Parkinson's study

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"2">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p><a href&equals;"http&colon;&sol;&sol;londonglossy&period;com&sol;wp-content&sol;uploads&sol;2011&sol;01&sol;star-fox-launches-parkinsons-study&period;jpg"><img class&equals;"alignnone size-full" title&equals;"Michael J Fox will launch a major study into the progression of Parkinson's disease" src&equals;"http&colon;&sol;&sol;londonglossy&period;com&sol;wp-content&sol;uploads&sol;2011&sol;01&sol;min-star-fox-launches-parkinsons-study&period;jpg" alt&equals;"Michael J Fox will launch a major study into the progression of Parkinson's disease"&sol;><&sol;a><&sol;p>&NewLine;<p>A major study into the progression of Parkinson&&num;8217&semi;s disease&comma; which will include British patients&comma; is being launched by actor Michael J Fox&period;<&sol;p>&NewLine;<p>The research is the first of its kind and will involve 400 people from five sites in Europe and 14 hospitals in the US&period;<&sol;p>&NewLine;<p>Patients in the earliest stages of Parkinson&&num;8217&semi;s &&num;8211&semi; before they have started any treatment &&num;8211&semi; will be enrolled in the study to find key biomarkers for the disease&period;<&sol;p>&NewLine;<p>Fox&comma; who was diagnosed with young-onset Parkinson&&num;8217&semi;s aged 30&comma; said the research was important because &&num;8220&semi;better treatments aren&&num;8217&semi;t going to fall from the sky&&num;8221&semi; and &&num;8220&semi;real challenges stand in the way of the results we need&&num;8221&semi;&period;<&sol;p>&NewLine;<p>Currently&comma; there is no definitive way of measuring how Parkinson&&num;8217&semi;s progresses&period; This means it is difficult for doctors to work out whether a drug is slowing down or halting the disease&&num;8217&semi;s advances&period;<&sol;p>&NewLine;<p>Reliable and robust biomarkers to monitor the progression of Parkinson&&num;8217&semi;s would improve patient care&comma; lead to new drugs and enhance understanding of the condition&period; Some 120&comma;000 Britons have Parkinson&&num;8217&semi;s&comma; which is caused by a loss of brain cells that produce a chemical messenger called dopamine&period;<&sol;p>&NewLine;<p>Symptoms include a tremor or fine shake while the person is at rest&comma; rigidity of muscles&comma; slowness of movement and an unsteady balance&period;<&sol;p>&NewLine;<p>In the new study&comma; samples taken from patients will help identify what is happening in the body&comma; and will include data on motor skills&comma; samples of blood&comma; urine and spinal fluid&comma; and brain scans&period; This data will be then used either alone or in combination to track progression of the disease&period;<&sol;p>&NewLine;<p>The research starts in early 2011 and is being co-ordinated and part-funded by the Micheal J Fox Foundation for Parkinson&&num;8217&semi;s Research&period; Debi Brooks&comma; co-founder of the Michael J Fox Foundation&comma; said patients will be followed for between three and five years&comma; and compared with healthy volunteers&period;<&sol;p>&NewLine;<p>As well as the US sites&comma; there will be research centres at Imperial College London&comma; one in Italy&comma; two in Germany and one in Austria&period; David Brooks&comma; professor of neurology at Imperial College&comma; London&comma; will lead the study at the UK site&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ee883bf172e">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ee883bf172e'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version